Atty Docket: ONYX1028-DIV Serial N . 10/054,435

Remarks

The above Amendments and these Remarks are in reply to the Office action mailed April 23, 2003

Claim Objections

Claims 3, 30 and 31 have been objected to because of certain informalities. Claim 3 has been amended to read "which is human" in place of "which is of human." Claims 30 and 31 have been cancelled.

Claim Rejection under 35 USC§ 112

Claims 1-6 are rejected under 35 USC § 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which Applicants regard as the invention. The Examiner has stated that the phrase "a biologically-active fragment" is indefinite because it does not define what the "activity" is. The Examiner will note that Applicants have cancelled claim 1, and amended claim 2 such that it is now the main independent claim. Claim 2 recites the language that the Examiner has indicated would overcome the objection.

Claim Rejection under 35 USC§ 102

Claims 1-3, 6, 30 and 31 are rejected under 35 U.S.C § 102(b) as being anticipated by WO 98/23743 (Davies et al.). Claims 1, 30 and 31 have been cancelled, thus the rejection as to them is moot. As for the remaining claims, Davies et al do not show each and every feature recited in claims 2, 3 and 6. Particularly not shown are the biological properties attributed to

Atty Docket: ONYX1028-DIV Serial No. 10/054,435

Applicants' Rac-GEF, and more particularly its amino acid sequence (SEQ. ID. NO:2). Since all these features claimed by the Applicants are not shown in Davies et al, it cannot be relied on to form the basis for a 102(b) rejection.

Claims 1, 2, 6 and 30 are rejected under 35 U.S.C. 102(b) as being anticipated by Chuang et al. Claims 1, and 30 have been cancelled, thus the rejection as to them is moot.

As for the remaining claims, 2 and 6, both recite (claim 6 by way of dependency) certain properties that their Rac-GEF, or biologically active fragments have that are not shown by Chuang et al. Particularly note that Applicants Rac-GEFs' have cellular oncogenic transforming activity. This is not shown by Chuang et al. Thus, Applicants respectfully request that the rejection based thereon be withdrawn.

Claims 1-3, 6 and 30 are rejected under 35 U.S.C. 102(b) as being anticipated by U.S. Patent No. 5,994,070 (Streuli et al). Claims 1 and 30 have been cancelled, thus the rejection as to them is moot. Regarding the remaining claims, claims 2, 3, and 6, these claims recite a feature of Applicants' Rac-GEFs not shown in the cited reference which is cellular oncogenic transforming activity. Thus, since this reference also does not show each and every feature claimed by the Applicants, the 102(b) rejection should be withdrawn.

## New Claims

The Examiner will note that Applicants have added two new claims, claims 68 and 69. These claim Rac-GEFs which are encoded by certain nucleotide sequences which either comprise at least 95% nucleotide sequence identity to the nucleotide sequence set forth in SEQ. ID. NO:1, or that hybridize, under stringent conditions, to the nucleotide sequence of SEQ. ID. NO: 1.

Atty Docket: ONYX1028-DIV Serial No. 10/054,435

The Commissioner is authorized to charge any underpayment or credit any overpayment to Deposit Account No. 15-0615 for any matter in connection with this response, including any fee for extension of time, which may be required. A duplicate copy of this authorization is enclosed.

The other papers enclosed or associated with this communication include:

- [X] A Petition for a Three Month extension of time
- [X] 5 Sheets of replacement drawings

Respectfully submitted,

Date: 10/22/03

Gregory Giotta

ONYX Pharmaccuticals, Inc. 3031 Research Drive Richmond, California 94806 Telephone (510) 262-8710

RECEIVED
CENTRAL FAX CENTER
OCT 2 2 2003

OFFICIAL

510-222-6767; Oct-2 Omyr Ser, No. 10/054, 435

8 716 3 ir አባለሚ ሁን Ser Alo Ser Asp Gin Irp Asn ገr Asp Asn Gu Hra Alo Lys Pai Lys Pro წյ leu kru Pro ሕጋ ዲሃን Gu Giu Inr Ser ሕገ Ao Asp, Gn Aup: ጉድ ICACTCAHACCASTSAAGCTIGGGAAASTCATIGACCTCCAGTCGTTCTGCTGAGAACATCTGGC:CTATITCCATGGASACCASGGAATC1GAAGATTGGAAAAGA LUCGUNGGAARTCAGCAAGTGATGAATGAACACTGATGAACCAGCCAAGBIGAAACCTGAGTTAC CCCAGAAAAAAAAGAGAGACTTCTCAAAGOTGACGAAGAAA II NAMEKAAAGAGESTEATISEEACATESEAAITAABAAATISEATETTEAAIEGETEEAIAAGAGEAAABSSAAGSSAAGSEAGAKAEAAACSSCAAGAAGSSAAC Met Git Ihr Arg Giu Ser Giu Asp teu Git tys had Ser Cysteel Alb Asp Ser Gin Asp Ash Ser Ast Ser Ash Sev Fro Leu Asr inchros Fro Ser Arg Mattro Pro Cystarg Fr Alb Met Gir Hy - Liver Specific Sequence a.a. 1-127 -- Liver Specific Sequence --Liver Specific Sequence — - Liver Specific Sequence -- 8.a. 1-127 -- 3.a. 1-127 B.a 1-127 Linear, Certain Sites Only, Slandard Genetic Code iver Rac GEF Map (1 > 3171) Site and Sequence All 478 enzymes (No Filter) : nzymes :

763 ć SEPPLO BY AD STORM SET SET SET SET SET FOR THE FORM HE FORM TO BE TO BE FORM THE SET FOR THE THE THE THE SET MOLES.

OCCOSTOR CALCEACCEATTECEGESACTEETGRASARACETEAT CAREAL AGGSCTOETSTATCASSAAT ACCEASARA FACTOR TARBARALE AGGARALE CAREARALE CAREARAL AND MELLIE HIS PRO HIE PRO ACH AND SEL IT PAND AND AND BEL BIN BAY LEULEN TYTING IN GN. TYTIANG KAPLYS SER ITT LEU BIT GN. HE GAN SANGOLIA (LANGOLIA CANGOLIA a.a. 216-226

--- Poly-Glutamate Region ---

Liver Specific Sequence 8.a. 1-127

CACCASAGAGAASACTOTSCOCOCAGATO TGCOTGC CAGTAACCOCCACT LAAGGITSAACCTOTSCAGATOTOCGGAGGATOGGGAGGAGGGGGGGGGGGTGCTTGASAI 

FIGURE 1-1

BEST AVAILABLE COPY

tes anny our up to tourne, an am recember of the Sensia Am Sensy hyperses recensules Wis Sensia Provider 65 Am PACEOSATAMOSABATICTOCACCOSTOCAGGCOACCTOCATOTOTOTOTAGGAGGGGCOACCTOCAGGAGGGGTTOTOTOTAGGAGGGGGGGGGG
(35) 4.00 (37) (37) (37) (37) (37) (37) (37) (37)
Ap Volum Ap Vol Ser Gu Arg Phe Leu Leu Gu Leu Gu me Arg ACTICTCI BICTACCA PICTACCA TO CANATOR AND LEU GU LE
a. 273-456
THE GALS AND HE FOR HE FOR ASPIRED FOR AND THE MORE AND THE SERVICE OF ACTION HE FOR THE FOR T
ity iya Çar səctəs Gh Gu tys Alo Aro Phe Arg Gu Leu ie Alo Gir teu Sc دود دود دود دود دود دود دود دود دود دو
CLITICCADASDATDAZACCCTCAASCTSTSSSTCCADAACATCTGAAGAGGSTACAAGAGAGGSTCTGACGGUASTSCACTGTTTGSATCTTCALAAGUAGCTSS
Du Homology Domain
AAATGGTSGTGGAAGSCATGCAACSASSECSTCAESAAATGALGGGTACSGAACAGATGATCAGCATTCABAASAAGATGGGGTTGAAGTGAGTGAGTTGAGTTGGTGTGT B.B. 273-456
BL GRY NO AND LYS MEI SHI MEY HET GLI GIN MEI THE SHITTE LYS SHOT GLI DHE LYS SUN YOT HO THE LYS SUN YOT HOUSE
a.a. 487-605 Pleckstrn Homology Domain
Sen His Sen Ang Tro Leu van Lys Gin Gy. Sul Leu Gin Sin Met Sen Gy. Pro Lys By Ang The Leu Ang The Leu Ang The By Leu Phe His Sin Tie Ty Leu Phe Costan Cost
Ter Pre Non Not Lou Lou Not Not 196 Sys Ang Gir. He Pro Giy Not Not Not Not Not Not Lou Lou Not

FIGURE 1-2

IN THE LEW AND LEW LEW COLD ASH AND ASH AND THE TWE THE LEW LYS AND SET SET CENTRES THE LYS AND COACCAMENT TO THE LEW AND COACCAMENT TO THE LAW AND
Pleckstrm Homology Domain Pleckstrm Homology Domain Pleckstrm An Pro Ass and An The Beauty See Beau
CAUCIDALDICIONANT MANAGEMENT CONTRACTOR NO SEL TRIB IN SER ANG LEU LEUAND COS POR NOI GO COS NOI HIS POR DATA AND NO OFFICE AND CONTRACTOR CONT
a.a. 608-680
Fig. 1931/Y 183 GN. Leu Ala Ago He Leu Aspring Thy Ago Ago Gy Fr. He Pile Gy G. Ann. Ann. Shariff Lui Anglay Forman Control Ago Gy Control Gy G. Ann. Ann. Ann. Ann. Ann. Ann. Ann. A
a.g. 608-680 Src Homology 3 Domain
Ser Ret into the leader that the life we ser done we have the the the the the harmous or the service of the service has been used. Toockastico
THE FACE CHARGE AND
MATARACCOSTOCICANCOLICICATIONAL TISTAMA, SALANACALITA CALLACTA TAGATICALA CALLACTA C
ICECTOCICECTOR TOCCCT 166CCCCA3634115CAA6AGGC CCCAACLEACACTOCTOTOCC CCAGA AAAA AAAAAAAAAAAAAAAAAAAAAAAAA
GICHTHI HADTIOGAABD76TASAATH7ACGAGGGAAAAGACGCGGCCC GCC1GAGGGGGGGGGGGG
UKAALINGORET GEGEREGETTEEGERAGGETET GEGAGGETET GOGERAGGETER GEGEREGEGERAGGET GELABAGET 19GET GOGERATION AND A
C'UTIGGOLUCO SAFOGODI SGA TOTOTO CON SECONO TAROS ROCCO ASOLISTI TAROS ASTORA HINDICAL TOTALCI GIALOSALIANO
USGAAANGCAANTATGGGAATTGT GGAGGCCGGGAAA GGGGGCATGCCGGAGGASTGSCCGGCGCGTGGGCCJGAAGCCGGGGAGCGGTAACGGAGGCTTAACGGAGGCTTAAGGGAGGCTTAAGGGAGGCTTAAGGGAGGCTTAAGGGAGGCTTAAGGGAGGCTTAAGGGAGGCTTAAGGGAGGCTTAAGGGAAGAGAAGAAAAAAAA
I CAUCCEAT COOCCEACTECTGGAGAAACO CA TGAACAAATAJGGCTCO GTATCAGGAATATGAGTA AA SA

FIGURE 1-3

Brain-Gowalic Sequence Map (1 > 184) Sile and Bequence	
Engines : Att 440 engines (No Filer)	
Sellinas: Linear, Option Print Drier, Standard Gerosic Code	
CAATTCCCOPACCCCTTAGTCCCCCCCCCCCCCCCCCCCCCCCCCCCCC	ACTOCT SECCESC TRECTT CASC
Bran Specific Sequence	
Ob. Pile the Chi the 168 flat Any the Any the Bar the Bar the Bay the Any the Any the Any the Sar The Any the Ato Ato Ato the Res that Ca	i laylay No No No PerSer.
GCCGCCTCCCCCTGBACTACGACTCCACCTCGBAAAGETUACGCGCGCCCCCCCCACCCCCACACCTCCCCCC	
Brian Specific Sequence	
Am Aim Cyr, dan Not Augo Hey Juay Sur Sur Sur Dar City Birt day Alle Ang Asp Sur Ato Ale City Nos Lots Pro Diy	

Figure 2




Figure 3




Figure 4




Figure 5




Figure 6